CA2435301A1 - Multi-arm block copolymers as drug delivery vehicles - Google Patents

Multi-arm block copolymers as drug delivery vehicles Download PDF

Info

Publication number
CA2435301A1
CA2435301A1 CA002435301A CA2435301A CA2435301A1 CA 2435301 A1 CA2435301 A1 CA 2435301A1 CA 002435301 A CA002435301 A CA 002435301A CA 2435301 A CA2435301 A CA 2435301A CA 2435301 A1 CA2435301 A1 CA 2435301A1
Authority
CA
Canada
Prior art keywords
block copolymer
polymer segment
arm block
poly
central core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002435301A
Other languages
French (fr)
Other versions
CA2435301C (en
Inventor
Xuan Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2435301A1 publication Critical patent/CA2435301A1/en
Application granted granted Critical
Publication of CA2435301C publication Critical patent/CA2435301C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C08G63/914—Polymers modified by chemical after-treatment derived from polycarboxylic acids and polyhydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/22—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the initiator used in polymerisation
    • C08G2650/24—Polymeric initiators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/05—Polymer mixtures characterised by other features containing polymer components which can react with one another

Abstract

The invention provides multi-arm block copolymers useful as drug delivery vehicles comprising a central core molecule, such as a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region. The solubility of hydrophobic biologically active agents can be improved by entrapment within the hydrophobic core region of the block copolymer. The invention further includes pharmaceutical compositions including such block copolymers, methods of making such copolymers and pharmaceutical compositions, and methods of using the block copolymers as drug delivery vehicles.

Claims (66)

1. A multi-arm block copolymer useful as a drug delivery vehicle, comprising:
a central core molecule comprising a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, at least one of the hydrophobic and hydrophilic polymer segments comprising at least one degradable linkage, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region.
2. The multi-arm block copolymer of Claim 1, wherein the central core molecule is a residue of a polyol selected from the group consisting of glycerol, sorbitol, pentaerythritol, and glycerol oligomers.
3. The multi-arm block copolymer of Claim 1, wherein the central core molecule is a residue of hexaglycerol.
4. The multi-arm block copolymer of Claim 1, wherein the central core molecule is a residue of hydroxypropyl-.beta.-cyclodextrin.
5. The multi-arm block copolymer of Claim 1, wherein the inner hydrophobic polymer segment is selected from the group consisting of a poly(hydroxyester), a poly(alkylene oxide) other than poly(ethylene glycol), or a copolymer thereof.
6. The multi-arm block copolymer of Claim 1, wherein the inner hydrophobic polymer segment is poly(propylene glycol).
7. The multi-arm block copolymer of Claim 1, wherein the inner hydrophobic polymer segment is a poly(hydroxyester) selected from the group consisting of poly(lactide), poly(glycolide), poly(lactide)/(glycolide) copolymer, poly(butyrolactide), and polycaprolactone.
8. The multi-arm block copolymer of Claim 1, wherein the outer hydrophilic polymer segment comprises poly(ethylene glycol).
9. The multi-arm block copolymer of Claim 1, wherein each hydrophobic and hydrophilic polymer segment has a molecular weight of about 500 Da to about 100,000 Da.
10. The multi-arm block copolymer of Claim 1, wherein the hydrophobic polymer segment has a molecular weight of about 10,000 Da to about 40,000 Da.
11. The multi-arm block copolymer of Claim 1, wherein the hydrophilic polymer segment has a molecular weight of about 1,000 Da to about 20,000 Da.
12. The multi-arm block copolymer of Claim 1, wherein the central core molecule is attached to at least 5 copolymer arms.
13. The multi-arm block copolymer of Claim 1, wherein the central core molecule is attached to at least 8 copolymer arms.
14. The multi-arm block copolymer of Claim 1, wherein the central core molecule is attached to at least 10 copolymer arms.
15. The multi-arm block copolymer of Claim 1, wherein at least one targeting moiety is covalently attached to at least one hydrophilic polymer segment.
16. The multi-arm block copolymer of Claim 15, wherein the targeting moiety is a bisphosphonate.
17. The multi-arm block copolymer of Claim 1, wherein at least one capping group is covalently attached to at least one hydrophilic polymer segment.
18. The multi-arm block copolymer of Claim 17, wherein the capping group is selected from the group consisting of alkoxy, hydroxyl, protected hydroxyl, active ester, active carbonate, acetal, aldehyde, aldehyde hydrates, alkyl or aryl sulfonate, halide, disulfide, alkenyl, acrylate, methacrylate, acrylamide, active sulfone, amine, protected amine, hydrazide, protected hydrazide, thiol, protected thiol, carboxylic acid, protected carboxylic acid, isocyanate, isothiocyanate, maleimide, vinylsulfone, dithiopyridine, vinylpyridine, iodoacetamide, epoxide, glyoxals, diones, mesylates, tosylates, or tresylate.
19. The multi-arm block copolymer of Claim 1, having the structure:
A(-O-B-O-C-D)n wherein:
A is a central core molecule comprising a residue of a polyol, O is oxygen, B is a hydrophobic polymer segment, C is a hydrophilic polymer segment, D is a capping group, and n is 3 to about 25.
20. The multi-arm block copolymer of Claim 19, wherein each D is alkoxy.
21. The multi-arm block copolymer of Claim 19, wherein each D is hydroxy.
22. The multi-arm block copolymer of Claim 19, wherein each D is selected from the group consisting of alkoxy, hydroxyl, protected hydroxyl, active ester, active carbonate, acetal, aldehyde, aldehyde hydrates, alkyl or aryl sulfonate, halide, disulfide, alkenyl, acrylate, methacrylate, acrylamide, active sulfone, amine, protected amine, hydrazide, protected hydrazide, thiol, protected thiol, carboxylic acid, protected carboxylic acid, isocyanate, isothiocyanate, maleimide, vinylsulfone, dithiopyridine, vinylpyridine, iodoacetamide, epoxide, glyoxals, diones, mesylates, tosylates, or tresylate.
23. The multi-arm block copolymer of Claim 19, wherein A is a residue of a polyol selected from the group consisting of glycerol, sorbitol, pentaerythritol, hydroxypropyl-.beta.-cyclodextrin, and glycerol oligomers.
24. The multi-arm block copolymer of Claim 19, wherein B is selected from the group consisting of a poly(hydroxyester), a poly(alkylene oxide) other than poly(ethylene glycol), or a copolymer thereof.
25. The multi-arm block copolymer of Claim 19, wherein B is poly(propylene oxide).
26. The multi-arm block copolymer of Claim 19, wherein B is a poly(hydroxyester) selected from the group consisting of poly(lactide), poly(glycolide), poly(lactide)/(glycolide) copolymer, poly(butyrolactide), and polycaprolactone.
27. The multi-arm block copolymer of Claim 19, wherein at least one of B
and C comprises at least one degradable linkage.
28. The multi-arm block copolymer of Claim 19, wherein C comprises poly(ethylene glycol).
29. The multi-arm block copolymer of Claim 19, wherein C comprises a hydrolyzable linkage selected from the group consisting of esters, carbonates, imines, hydrazone, phosphate esters, orthoesters, peptides, or acetals.
30. The multi-arm block copolymer of Claim 1, having the structure:
(E-C-O-B-O-)p A(-O-B-O-C-D)m, wherein:
A is a central core molecule moiety comprising a residue of a polyol, O is oxygen, B is a hydrophobic polymer segment, C is a hydrophilic polymer segment, D is a hydroxyl or alkoxy group, p is at least 1, the sum of m and p is from 3 to about 25, and E is a functional group selected from the group consisting of active ester, active carbonate, acetal, aldehyde, aldehyde hydrates, alkyl or aryl sulfonate, halide, disulfide, alkenyl, acrylate, methacrylate, acrylamide, active sulfone, amine, protected amine, hydrazide, protected hydrazide, thiol, protected thiol, carboxylic acid, protected carboxylic acid, isocyanate, isothiocyanate, maleimide, vinylsulfone, dithiopyridine, vinylpyridine, iodoacetamide, epoxide, glyoxals, diones, mesylates, tosylates, or tresylate.
31. The multi-arm block copolymer of Claim 1, having the structure:
(T-C-O-B-O-)p A(-O-B-O-C-D)m wherein:
A is a central core molecule moiety comprising a residue of a polyol, O is oxygen, B is a hydrophobic polymer segment, C is a hydrophilic polymer segment, D is a capping group, p is at least 1, the sum of m and p is from 3 to about 25, and T is a targeting moiety.
32. The multi-arm block copolymer of Claim 31, wherein T is selected from the group consisting of a protein, an antibody, an antibody fragment, a peptide, a carbohydrate, a lipid, an oligonucleotide, DNA, RNA, and a small molecule having molecular weight less than 2000 Daltons.
33. The multi-arm block copolymer of Claim 31, wherein T is a bisphosphonate.
34. A multi-arm block copolymer useful as a drug delivery vehicle, comprising:

a central core molecule comprising a residue of a polyol, and at least five copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region.
35. The multi-arm block copolymer of Claim 34, wherein the central core molecule is a residue of a polyol selected from the group consisting of glycerol, sorbitol, pentaerythritol, and glycerol oligomers.
36. The multi-arm block copolymer of Claim 34, wherein the inner hydrophobic polymer segment is selected from the group consisting of a poly(hydroxyester), a poly(alkylene oxide) other than poly(ethylene glycol), or a copolymer thereof.
37. The multi-arm block copolymer of Claim 34, wherein the inner hydrophobic polymer segment is a poly(hydroxyester) selected from the group consisting of poly(lactide), poly(glycolide), poly(lactide)/(glycolide) copolymer, and polycaprolactone.
38. The multi-arm block copolymer of Claim 34, wherein at least one of the inner hydrophobic polymer segment and the outer hydrophilic polymer segment comprises at least one degradable linkage.
39. The multi-arm block copolymer of Claim 34, wherein the outer hydrophilic polymer segment comprises poly(ethylene glycol).
40. The multi-arm block copolymer of Claim 34, wherein the central core molecule is attached to at least 8 copolymer arms.
41. The multi-arm block copolymer of Claim 34, wherein the central core molecule is attached to at least 10 copolymer arms.
42. The multi-arm block copolymer of Claim 34, wherein at least one targeting moiety is covalently attached to at least one hydrophilic polymer segment.
43. The multi-arm block copolymer of Claim 42, wherein the targeting moiety is a bisphosphonate.
44. The multi-arm block copolymer of Claim 34, wherein at least one capping group is covalently attached to at least one hydrophilic polymer segment.
45. The multi-arm block copolymer of Claim 44, wherein the capping group is selected from the group consisting of alkoxy, hydroxyl, protected hydroxyl, active ester, active carbonate, acetal, aldehyde, aldehyde hydrates, alkyl or aryl sulfonate, halide, disulfide, alkenyl, acrylate, methacrylate, acrylamide, active sulfone, amine, protected amine, hydrazide, protected hydrazide, thiol, protected thiol, carboxylic acid, protected carboxylic acid, isocyanate, isothiocyanate, maleimide, vinylsulfone, dithiopyridine, vinylpyridine, iodoacetamide, epoxide, glyoxals, diones, mesylates, tosylates, or tresylate.
46. A pharmaceutical composition, comprising:
a multi-arm block copolymer, the block copolymer comprising a central core molecule comprising a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region, and at least one biologically active agent entrapped within the hydrophobic core region of the multi-arm block copolymer.
47. The pharmaceutical composition of Claim 46, wherein the biologically active agent is selected from the group consisting of 3,4-di-[1-methyl 6-nitro-indolyl]-1H-pyrrole-2,5-dione (MNIPD), simvastatin, indomethacin, pivaloyloxymethyl butyrate, cyclosporin A, paclitaxel, analogs thereof, and pharmaceutically acceptable salts thereof.
48. The pharmaceutical composition of Claim 46, wherein the central core molecule is a residue of a polyol selected from the group consisting of glycerol, sorbitol, pentaerythritol, hydroxypropyl-.beta.-cyclodextrin, and glycerol oligomers.
49. The pharmaceutical composition of Claim 46, wherein the inner hydrophobic polymer segment is selected from the group consisting of a poly(hydroxyester), a poly(alkylene oxide) other than polyethylene glycol), or a copolymer thereof.
50. The pharmaceutical composition of Claim 46, wherein the inner hydrophobic polymer segment is poly(propylene glycol).
51. The pharmaceutical composition of Claim 46, wherein the inner hydrophobic polymer segment is a poly(hydroxyester) selected from the group consisting of poly(lactide), poly(glycolide), poly(lactide)/(glycolide) copolymer, poly(butyrolactide), and polycaprolactone.
52. The pharmaceutical composition of Claim 46, wherein at least one of the inner hydrophobic polymer segment and the outer hydrophilic polymer segment comprises at least one degradable linkage.
53. The pharmaceutical composition of Claim 46, wherein the outer hydrophilic polymer segment comprises poly(ethylene glycol).
54. The pharmaceutical composition of Claim 46, wherein each hydrophobic and hydrophilic polymer segment has a molecular weight of about 500 Da to about 100,000 Da.
55. The pharmaceutical composition of Claim 46, wherein the hydrophobic polymer segment has a molecular weight of about 10,000 Da to about 40,000 Da.
56. The pharmaceutical composition of Claim 46, wherein the hydrophilic polymer segment has a molecular weight of about 1,000 Da to about 20,000 Da.
57. The pharmaceutical composition of Claim 46, wherein the central core molecule is attached to at least 5 copolymer arms.
58. The pharmaceutical composition of Claim 46, wherein the central core molecule is attached to at least 8 copolymer arms.
59. The pharmaceutical composition of Claim 46, wherein at least one targeting moiety is covalently attached to at least one hydrophilic polymer segment.
60. A method of preparing a pharmaceutical composition, comprising:
providing a multi-arm block copolymer, the block copolymer comprising a central core molecule comprising a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region, and entrapping a biologically active agent within the hydrophobic core region of the multi-arm block copolymer.
61. The method of Claim 60, wherein said entrapping step comprises dissolving the multi-arm block copolymer and biologically active agent in an organic solvent to form a mixture and drying the mixture to form a solid pharmaceutical composition.
62. The method of Claim 60, wherein said entrapping step comprises suspending the biologically active agent in an aqueous solution of the multi-arm block copolymer and subjecting the solution to ultrasonication.
63. The method of Claim 60, wherein said entrapping step comprises mixing the biologically active agent and multi-arm block copolymer in solid form, heating the mixture to form a melt, and stirring the mixture to intimately mix the biologically active moiety and the multi-arm block copolymer.
64. A method of delivering a biologically active agent to a mammal, comprising:~
administering a therapeutically effective amount of a pharmaceutical composition to the mammal, the pharmaceutical composition comprising:
a multi-arm block copolymer, the block copolymer comprising a central core molecule comprising a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region, and at least one biologically active agent entrapped within the hydrophobic core region of the multi-arm block copolymer.
65. The method of Claim 64, wherein the biologically active agent is selected from the group consisting of 3,4-di-[1-methyl 6-nitro-3-indolyl]-1H-pyrrole-2,5-dione (MNIPD), simvastatin, indomethacin,, pivaloyloxymethyl butyrate, cyclosporin A, paclitaxel, analogs thereof, and pharmaceutically acceptable salts thereof.
66. The method of Claim 64, wherein said administering step comprises administering by oral, buccal, rectal, topical, nasal, ophthalmic, parenteral, or inhalation routes.
CA2435301A 2001-01-19 2002-01-22 Multi-arm block copolymers as drug delivery vehicles Expired - Lifetime CA2435301C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26275401P 2001-01-19 2001-01-19
US60/262,754 2001-01-19
PCT/US2002/021872 WO2003000777A2 (en) 2001-01-19 2002-01-22 Multi-arm block copolymers as drug delivery vehicles

Publications (2)

Publication Number Publication Date
CA2435301A1 true CA2435301A1 (en) 2003-01-03
CA2435301C CA2435301C (en) 2010-04-13

Family

ID=22998880

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2435301A Expired - Lifetime CA2435301C (en) 2001-01-19 2002-01-22 Multi-arm block copolymers as drug delivery vehicles

Country Status (12)

Country Link
US (6) US6730334B2 (en)
EP (1) EP1373366B1 (en)
JP (1) JP4078300B2 (en)
KR (1) KR100851270B1 (en)
AT (1) ATE313586T1 (en)
AU (1) AU2002326369B2 (en)
CA (1) CA2435301C (en)
DE (1) DE60208172T2 (en)
ES (1) ES2254717T3 (en)
MX (1) MXPA03006449A (en)
TW (1) TWI246524B (en)
WO (1) WO2003000777A2 (en)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) * 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US7009033B2 (en) * 2001-07-02 2006-03-07 Polymer Source Inc. Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
KR20040040782A (en) * 2002-11-08 2004-05-13 선바이오(주) Novel hexa-arm polyethylene glycol and its derivatives and the methods of preparation thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP2005008614A (en) * 2003-03-28 2005-01-13 Nano Career Kk Drug delivery system for ophthalmology by using macromolecular micelle
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
TWI248947B (en) * 2003-07-21 2006-02-11 Ind Tech Res Inst Biodegradable copolymer, and polymeric micelle composition containing the copolymer
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
KR100703872B1 (en) * 2003-10-10 2007-04-09 주식회사 삼양사 Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US20050214250A1 (en) 2003-11-06 2005-09-29 Harris J M Method of preparing carboxylic acid functionalized polymers
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
WO2005074524A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
US7354980B1 (en) 2004-03-12 2008-04-08 Key Medical Technologies, Inc. High refractive index polymers for ophthalmic applications
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
JP4733113B2 (en) * 2004-05-05 2011-07-27 フイルメニツヒ ソシエテ アノニム Biodegradable graft copolymer
US7618778B2 (en) 2004-06-02 2009-11-17 Kaufman Joseph C Producing, cataloging and classifying sequence tags
KR101699142B1 (en) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 Novel antigen-binding polypeptides and their uses
EP2359842A1 (en) 2004-07-14 2011-08-24 University of Utah Research Foundation Netrin-related compositions and uses
ES2618028T3 (en) 2004-07-19 2017-06-20 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof.
EP1814924A2 (en) * 2004-10-08 2007-08-08 Firmenich Sa Amphiphilic star block copolymers
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US7446157B2 (en) 2004-12-07 2008-11-04 Key Medical Technologies, Inc. Nanohybrid polymers for ophthalmic applications
PT2730277T (en) 2004-12-22 2020-04-21 Nitto Denko Corp Drug carrier and drug carrier kit for inhibiting fibrosis
CN103290084A (en) 2004-12-22 2013-09-11 Ambrx公司 Method for expression and purification of recombinant human growth hormone
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
MX2007007587A (en) 2004-12-22 2007-12-11 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid.
JP4990792B2 (en) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド Compositions of aminoacyl-tRNA synthetases and uses thereof
KR20080009196A (en) * 2005-04-12 2008-01-25 위스콘신 얼럼나이 리서어치 화운데이션 Micelle composition of polymer and passenger drug
US20060263328A1 (en) * 2005-05-19 2006-11-23 Sang Van Hydrophilic polymers with pendant functional groups and method thereof
KR100664558B1 (en) 2005-05-23 2007-01-03 박기동 Amphiphilic copolymer having multi functional group and preparation method thereof
JP2008541769A (en) 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド Improved human interferon molecules and their use
CA2653541C (en) 2005-06-06 2014-12-23 The University Of British Columbia Polymer-based serum albumin substitute
EP1898955A2 (en) * 2005-06-17 2008-03-19 Nektar Therapeutics AL, Corporation Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
KR100642220B1 (en) * 2005-07-12 2006-11-03 광주과학기술원 Conjugates of cyclodextrin and poly(oxyethylene) and process for preparation thereof
US20090062909A1 (en) * 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2615452C (en) 2005-07-15 2015-03-31 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
EP1926768B1 (en) * 2005-07-18 2011-09-14 Nektar Therapeutics Branched functionalized polymers using branched polyol cores
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
JP5264492B2 (en) * 2005-10-25 2013-08-14 エボニック デグサ ゲーエムベーハー Preparations containing hyperbranched polymers
DE102005051342A1 (en) * 2005-10-25 2007-04-26 Goldschmidt Gmbh Encapsulation and controlled release of biologically active drugs with enzymatically degradable hyperbranched carrier polymers
CA2626522A1 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
PL1979407T3 (en) 2006-01-19 2015-03-31 Allexcel Inc Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
MX2008010841A (en) 2006-02-21 2008-10-27 Nektar Therapeutics Al Corp Segmented degradable polymers and conjugates made therefrom.
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
WO2007133807A2 (en) * 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100015068A1 (en) * 2006-07-06 2010-01-21 Massachusetts Institute Of Technology Methods and Compositions For Altering Biological Surfaces
US20100047258A1 (en) * 2006-08-02 2010-02-25 Dong Wang Drug Carriers, Their Synthesis, and Methods of Use Thereof
US20100022481A1 (en) * 2006-08-02 2010-01-28 Dong Wang Drug Carriers, Their Synthesis, and Methods of Use Thereof
DE102006038240A1 (en) * 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Process for the preparation of a composite of oligo- or polynucleotides and hydrophobic biodegradable polymers and composite obtained by the process
CN101511856B (en) 2006-09-08 2016-01-20 Ambrx公司 In vertebrate cells, suppressor trna transcribes
JP5399906B2 (en) 2006-09-08 2014-01-29 アンブルックス，インコーポレイテッド Hybrid suppressor TRNA for vertebrate cells
CN106008699A (en) * 2006-09-08 2016-10-12 Ambrx公司 Modified human plasma polypeptide or Fc scaffolds and their uses
WO2008042909A2 (en) 2006-10-02 2008-04-10 Micell Technologies Inc. Surgical sutures having increased strength
CA2667228C (en) * 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US20080153982A1 (en) * 2006-12-20 2008-06-26 John Ta-Yuan Lai Vinyl-Thiocarbonate and Polyol Containing Block Copolymers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
JP5052919B2 (en) * 2007-03-08 2012-10-17 成均▲館▼大學校 産學協力團 PH and temperature sensitive block copolymer hydrogel
CN107501407B (en) 2007-03-30 2022-03-18 Ambrx公司 Modified FGF-21 polypeptides and uses thereof
TWI407971B (en) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
CA2684482C (en) * 2007-04-17 2014-08-12 Micell Technologies, Inc. Stents having biodegradable layers
EP1982698A1 (en) * 2007-04-18 2008-10-22 Evonik Degussa GmbH Preparations for controlled release of natural bioactive materials
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
ATE530178T1 (en) 2007-05-23 2011-11-15 Amcol International Corp PHYLLOSSILICATES INTERACTING WITH CHOLESTEROL AND METHOD FOR REDUCING HYPERCHOLESTEROLEMIA IN A MAMMAL
AU2008256684B2 (en) * 2007-05-25 2012-06-14 Micell Technologies, Inc. Polymer films for medical device coating
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance
CN101801180A (en) 2007-07-16 2010-08-11 艾尔维奥血管公司 antimicrobial constructs
US20110130822A1 (en) * 2007-07-20 2011-06-02 Orbusneich Medical, Inc. Bioabsorbable Polymeric Compositions and Medical Devices
JP2010539245A (en) 2007-09-14 2010-12-16 日東電工株式会社 Drug carrier
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
EP3424525A1 (en) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2009051780A1 (en) * 2007-10-19 2009-04-23 Micell Technologies, Inc. Drug coated stents
EP2214716B1 (en) * 2007-10-23 2021-11-17 Nektar Therapeutics Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
KR101024742B1 (en) * 2007-12-31 2011-03-24 주식회사 삼양사 Amphiphilic Block Copolymer Micelle Composition Containing Taxane and Manufacturing Process of The Same
US9801818B2 (en) 2007-12-31 2017-10-31 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
NZ620606A (en) 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses
TWI395593B (en) 2008-03-06 2013-05-11 Halozyme Inc In vivo temporal control of activatable matrix-degrading enzymes
CA3096629A1 (en) 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
EP2271294B1 (en) 2008-04-17 2018-03-28 Micell Technologies, Inc. Stents having bioabsorbable layers
TWI394580B (en) 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions
AU2009268528B2 (en) * 2008-07-09 2015-11-05 Board Of Regents Of The University Of Nebraska Functional micelles for hard tissue targeted delivery of chemicals
JP2011528275A (en) * 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． Drug delivery medical device
PE20110426A1 (en) 2008-07-23 2011-07-01 Ambrx Inc MODIFIED BOVINE G-CSF POLYPEPTIDES
US9991391B2 (en) * 2008-07-25 2018-06-05 The Board Of Trustees Of The Leland Stanford Junior University Pristine and functionalized graphene materials
ES2744975T3 (en) 2008-09-23 2020-02-27 Nektar Therapeutics Metronome dosage method with camptothecin prodrugs (eg PEG-Irinotecan)
CN107022020A (en) 2008-09-26 2017-08-08 Ambrx公司 The animal erythropoietin polypeptides and its purposes of modification
CN102224238B (en) 2008-09-26 2015-06-10 Ambrx公司 Non-natural amino acid replication-dependent microorganisms and vaccines
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CN101724144A (en) 2008-11-03 2010-06-09 北京键凯科技有限公司 Novel multi-arm polyethylene glycol, preparation method and application thereof
SG172064A1 (en) 2008-12-09 2011-07-28 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
WO2010111238A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Improved biodegradable polymers
CA2756307C (en) * 2009-03-23 2017-08-08 Micell Technologies, Inc. Peripheral stents having layers and reinforcement fibers
US20100239635A1 (en) 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
CN102481195B (en) * 2009-04-01 2015-03-25 米歇尔技术公司 Drug delivery medical device
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
CN101869712B (en) * 2009-04-21 2016-01-20 财团法人工业技术研究院 The polymeric micelle of encapsulation antitumor drug is used to be used for the treatment of the pharmaceutical composition of tumor
US9572693B2 (en) 2009-05-14 2017-02-21 Orbusneich Medical, Inc. Self-expanding stent with polygon transition zone
US8013065B2 (en) * 2009-06-09 2011-09-06 International Business Machines Corporation Methods for making multi-branched polymers
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc Drug delivery medical device
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US20110070320A1 (en) * 2009-09-23 2011-03-24 Soonkap Hahn Biodegradable thermoresponsive 3-arm polyethylene glycol poly(lactide-co-glycolide) copolymer for ginseng administration
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
CA2784800A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
EP2542613A4 (en) 2010-03-01 2013-12-11 Univ British Columbia Derivatized hyperbranched polyglycerols
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US8765098B2 (en) 2010-03-30 2014-07-01 International Business Machines Corporation Star polymers, methods of preparation thereof, and uses thereof
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2571896A4 (en) 2010-05-17 2014-01-08 Cebix Inc Pegylated c-peptide
KR101822684B1 (en) 2010-06-25 2018-01-26 이 아이 듀폰 디 네모아 앤드 캄파니 polyoxymethylene compositions with Branched Polymers
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
CA2806058C (en) 2010-07-20 2016-09-13 Halozyme, Inc. Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
RS59193B1 (en) 2010-08-17 2019-10-31 Ambrx Inc Modified relaxin polypeptides and their uses
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
US20140037574A1 (en) * 2010-11-26 2014-02-06 Pius Sedowhe Fasinu Pharmaceutical composition
WO2012092504A2 (en) 2010-12-30 2012-07-05 Micell Technologies, Inc. Nanoparticle and surface-modified particulate coatings, coated balloons, and methods therefore
ES2634669T3 (en) 2011-02-08 2017-09-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan degradation enzyme and use thereof for the treatment of benign prostatic hyperplasia
EP2696815B1 (en) 2011-04-13 2019-03-20 Micell Technologies, Inc. Stents having controlled elution
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
WO2012174480A2 (en) 2011-06-17 2012-12-20 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US8445577B2 (en) * 2011-07-25 2013-05-21 Iowa State University Research Foundation, Inc. Amphiphilic multi-arm copolymers and nanomaterials derived therefrom
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN104093415B (en) 2011-10-24 2017-04-05 哈洛齐梅公司 Companion's diagnostic agent and its using method of anti-hyaluronan agent therapy
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
TR201802761T4 (en) 2012-03-30 2018-03-21 Univ Oklahoma High molecular weight heparosan polymers and methods for their production and use.
PT2833905T (en) 2012-04-04 2018-08-06 Halozyme Inc Combination therapy with hyaluronidase and a tumor-targeted taxane
WO2013176739A1 (en) * 2012-05-25 2013-11-28 Regents Of The University Of Minnesota Biomaterials with a sustainable surface
CA2875989A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
HUE045227T2 (en) 2012-08-31 2019-12-30 Sutro Biopharma Inc Modified amino acids comprising an azido group
CN102861610B (en) * 2012-09-03 2014-05-07 宁波长阳科技有限公司 Hyperbranched amido pyridine contained catalyst, preparation methods of catalyst and application of catalyst
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CN103910874A (en) * 2013-01-06 2014-07-09 张雅珍 Preparation and application of medicine-grafted polymer
CN104193987A (en) * 2013-01-21 2014-12-10 张雅珍 Preparation and uses of grafted medicine polymers
KR20150143476A (en) 2013-03-12 2015-12-23 미셀 테크놀로지즈, 인코포레이티드 Bioabsorbable biomedical implants
WO2014172261A1 (en) * 2013-04-15 2014-10-23 Kent State University Biodegradable side chain liquid crystal elastomers: smart responsive scaffolds (srs) for tissue regeneration
KR102079613B1 (en) 2013-05-15 2020-02-20 미셀 테크놀로지즈, 인코포레이티드 Bioabsorbable biomedical implants
TW201534726A (en) 2013-07-03 2015-09-16 Halozyme Inc Thermally stable PH20 hyaluronidase variants and uses thereof
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
CN104910373A (en) * 2013-08-25 2015-09-16 张雅珍 New polymer, preparation and application thereof
EP3043698B1 (en) 2013-09-09 2017-10-18 Gambro Lundia AB Separation of interference pulses from physiological pulses in a pressure signal
WO2015038966A1 (en) * 2013-09-12 2015-03-19 Regents Of The University Of Minnesota Semi-solid delivery systems
US9433638B1 (en) 2013-10-02 2016-09-06 University Of Kentucky Research Foundation Polymeric prodrug
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3164111B1 (en) 2014-07-02 2019-04-03 The Research Foundation for the State University of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
HUE043847T2 (en) 2014-08-28 2019-09-30 Halozyme Inc Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
NZ746680A (en) 2014-10-14 2020-07-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PT3412302T (en) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
CN105395483B (en) * 2015-12-21 2018-09-28 江南大学 One kind can deoxidization, degradation dissaving polymer nano-micelle and preparation method thereof
US10792477B2 (en) 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
CN110201242A (en) 2016-02-08 2019-09-06 祥丰医疗私人有限公司 A kind of medical device
CN105778021B (en) * 2016-04-05 2018-07-10 华南理工大学 Beta-cyclodextrin base star polymer and preparation method and its unimolecular micelle diagnosis and treatment integral system
EP3512560A4 (en) 2016-09-13 2020-05-27 Rasna Research Inc. Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
US20180085498A1 (en) 2016-09-23 2018-03-29 Micell Technologies, Inc. Prolonged drug-eluting products
US11027040B2 (en) * 2016-12-29 2021-06-08 Industrial Technology Research Institute Method for manufacturing a porous film, porous film and method for tissue adhesion
CN110637027A (en) 2017-02-08 2019-12-31 百时美施贵宝公司 Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof
BR112019027583A2 (en) 2017-06-22 2020-10-06 Catalyst Biosciences, Inc. modified membrane-like serine protease 1 (mtsp-1) polypeptides and methods of use
US10457759B2 (en) 2017-07-20 2019-10-29 International Business Machines Corporation Co-delivery of cholesterol lowering drugs and nutraceuticals
CA3086992C (en) * 2017-12-27 2023-05-02 Sanyo Chemical Industries, Ltd. Starting material for bulk drug or additives for drug, and bulk drug or drug using same
CN108707212B (en) * 2018-05-02 2020-01-07 上海交通大学 Controllable preparation method of water-soluble conjugated polymer nanoparticles
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
SG11202102427XA (en) 2018-09-11 2021-04-29 Ambrx Inc Interleukin-2 polypeptide conjugates and their uses
EP3867265A1 (en) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CN109608633A (en) * 2018-11-09 2019-04-12 北京诺康达医药科技股份有限公司 A kind of novel specific multi-arm polyethylene glycol derivative and preparation method thereof
WO2020140101A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
EP3680273B1 (en) * 2019-01-08 2022-03-09 Université de Montpellier Branched-block copolymer photo-crosslinker functionalized with photoreactive groups and its use for shaping degradable photo-crosslinked elastomers suitable for medical and tissue-engineering applications
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
CN109929083B (en) 2019-04-10 2020-04-28 浙江大学 Narrow molecular weight distribution multi-block copolymer and preparation method thereof
CN110078901A (en) * 2019-05-24 2019-08-02 上海典范医疗科技有限公司 A kind of poly-dl-lactide preparation method
EP3862032A1 (en) 2020-02-07 2021-08-11 Micell Technologies, Inc. Stents having biodegradable layers
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
CN111759552A (en) 2020-07-06 2020-10-13 苏州莱诺医疗器械有限公司 Absorbable stent system
EP4199968A1 (en) 2020-08-20 2023-06-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
CN113416302B (en) * 2021-07-08 2022-06-17 中国科学院兰州化学物理研究所 Mercaptan-acrylate biomaterial and preparation method and application thereof
CN114713206B (en) * 2022-03-15 2023-11-14 沈阳工业大学 Preparation and application of imidazole ionic liquid functionalized star-type block polymer stationary phase

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US673034A (en) * 1900-08-07 1901-04-30 Russel B Sigafoos Trussed ladder.
US3101374A (en) * 1958-08-19 1963-08-20 Wyandotte Chemicals Corp Polyoxyalkylene surface active agents having heteric polyoxyethylene solubilizing chains
US4278555A (en) * 1978-11-15 1981-07-14 Ethyl Corporation Lubricant composition
AU537741B2 (en) 1979-03-21 1984-07-12 British Technology Group Limited Controlled release compositions
JPS59155432A (en) 1983-02-22 1984-09-04 Rikagaku Kenkyusho Surface-modified polymer having molecular chain of large mobility
US5135751A (en) 1988-11-16 1992-08-04 Mediventures Incorporated Composition for reducing postsurgical adhesions
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US5681576A (en) 1988-11-16 1997-10-28 Mdv Technologies, Inc. Method and composition for post surgical adhesion reduction
US5306501A (en) 1990-05-01 1994-04-26 Mediventures, Inc. Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers
DE4017688A1 (en) 1990-06-01 1991-12-05 Bayer Ag IMPROVED FUNCTIONAL LIQUIDS AND NEW POLYOXYALKYLENE POLYMERS
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
CA2087125A1 (en) * 1992-01-23 1993-07-24 Mridula Nair Chemically fixed micelles
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5618528A (en) 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
PT876165E (en) 1995-12-18 2006-10-31 Angiotech Biomaterials Corp COMPOSITIONS OF RETICULATED POLYMERS AND PROCESSES FOR THEIR USE
US5610241A (en) 1996-05-07 1997-03-11 Cornell Research Foundation, Inc. Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
AR018528A1 (en) 1997-12-12 2001-11-28 Expression Genetics Inc BIODEGRADABLE POLYMER MIXTURE OF MICELS FOR GENETIC TRANSFER
DK1053019T3 (en) 1998-01-07 2004-04-13 Debio Rech Pharma Sa Degradable heterobifunctional polyethylene glycol acrylates and gels and conjugates derived therefrom
JP4078032B2 (en) * 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション Poly (ethylene glycol) derivatives with proximal reactive groups
US20030059465A1 (en) * 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6328988B1 (en) * 1999-04-23 2001-12-11 Rutgers, The State University Of New Jersey Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
JP2003520210A (en) 2000-01-05 2003-07-02 イマレックス セラピューティクス， インコーポレイテッド Pharmaceutical formulations for delivery of drugs with low water solubility
FI109162B (en) * 2000-06-30 2002-05-31 Nokia Corp Method and arrangement for decoding a convolution-coded codeword
US7265186B2 (en) * 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
TWI246524B (en) * 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles

Also Published As

Publication number Publication date
KR20040032092A (en) 2004-04-14
JP2004531627A (en) 2004-10-14
TWI246524B (en) 2006-01-01
DE60208172D1 (en) 2006-01-26
US6730334B2 (en) 2004-05-04
US8071692B2 (en) 2011-12-06
DE60208172T2 (en) 2006-07-13
US20130144014A1 (en) 2013-06-06
EP1373366B1 (en) 2005-12-21
CA2435301C (en) 2010-04-13
WO2003000777A3 (en) 2003-05-01
ATE313586T1 (en) 2006-01-15
US7589157B2 (en) 2009-09-15
AU2002326369B2 (en) 2007-03-15
US20080234430A1 (en) 2008-09-25
US20120046422A1 (en) 2012-02-23
US20020156047A1 (en) 2002-10-24
JP4078300B2 (en) 2008-04-23
KR100851270B1 (en) 2008-08-08
US20090299050A1 (en) 2009-12-03
US8586681B2 (en) 2013-11-19
US6838528B2 (en) 2005-01-04
ES2254717T3 (en) 2006-06-16
EP1373366A2 (en) 2004-01-02
MXPA03006449A (en) 2004-10-15
US20040170595A1 (en) 2004-09-02
US8338545B2 (en) 2012-12-25
WO2003000777A2 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
CA2435301A1 (en) Multi-arm block copolymers as drug delivery vehicles
JP4465109B2 (en) Polymer prodrugs of amino and hydroxyl containing bioactive agents
JP5031164B2 (en) Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6251382B1 (en) Biodegradable high molecular weight polymeric linkers and their conjugates
US6180095B1 (en) Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1448666B1 (en) Bioerodible poly(ortho esters) containing amine groups, and block copolymers containing them
US8088365B2 (en) Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
KR101045504B1 (en) Multi-arm polypeptide-polyethylene glycol block copolymers as drug delivery vehicles
CA2757645C (en) Methods and materials for delivering molecules
US7265186B2 (en) Multi-arm block copolymers as drug delivery vehicles
JP2010235624A (en) Trialkyl-lock-facilitated polymeric prodrug of amino-containing bioactive agent
US7456213B2 (en) PEG-poly(ortho ester) graft copolymers and pharmaceutical compositions
US6214330B1 (en) Coumarin and related aromatic-based polymeric prodrugs

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220124